These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
845 related articles for article (PubMed ID: 30938373)
1. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373 [TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A; Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635 [TBL] [Abstract][Full Text] [Related]
3. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511 [TBL] [Abstract][Full Text] [Related]
4. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes. Chen JW; Borgelt LM; Blackmer AB Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356 [TBL] [Abstract][Full Text] [Related]
5. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312 [TBL] [Abstract][Full Text] [Related]
6. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. Golub V; Reddy DS Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006 [TBL] [Abstract][Full Text] [Related]
7. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome. Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899 [TBL] [Abstract][Full Text] [Related]
8. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome. Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197 [TBL] [Abstract][Full Text] [Related]
9. Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Wechsler RT; Burdette DE; Gidal BE; Hyslop A; McGoldrick PE; Thiele EA; Valeriano J Epilepsia Open; 2024 Oct; 9(5):1632-1642. PubMed ID: 39007525 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221 [TBL] [Abstract][Full Text] [Related]
11. Source of cannabinoids: what is available, what is used, and where does it come from? Specchio N; Pietrafusa N; Cross HJ Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. Reddy DS Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806 [TBL] [Abstract][Full Text] [Related]
13. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain. García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101 [TBL] [Abstract][Full Text] [Related]
14. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol. Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026 [TBL] [Abstract][Full Text] [Related]
15. Cannabis for the Treatment of Epilepsy: an Update. Gaston TE; Szaflarski JP Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563 [TBL] [Abstract][Full Text] [Related]
16. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K; Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273 [TBL] [Abstract][Full Text] [Related]
17. Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea. Koo CM; Kim SH; Lee JS; Park BJ; Lee HK; Kim HD; Kang HC J Korean Med Sci; 2020 Dec; 35(50):e427. PubMed ID: 33372424 [TBL] [Abstract][Full Text] [Related]
18. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey. Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688 [TBL] [Abstract][Full Text] [Related]
19. Cannabidiol use in patients with Dravet syndrome and Lennox-Gastaut syndrome: experts' opinions using a nominal group technique (NGT) approach. Bonanni P; Ragona F; Fusco C; Gambardella A; Operto FF; Parmeggiani L; Sartori S; Specchio N Expert Opin Pharmacother; 2023 Apr; 24(5):655-663. PubMed ID: 37021712 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Franco V; Perucca E Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]